{"name":"Viatris Specialty LLC","slug":"viatris-specialty-llc","ticker":"","exchange":"","domain":"viatrisspecialtyllc.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharmaceuticals","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"diazepam 20 mg","genericName":"diazepam 20 mg","slug":"diazepam-20-mg","indication":"Other","status":"marketed"},{"name":"gabapentin 600 mg","genericName":"gabapentin 600 mg","slug":"gabapentin-600-mg","indication":"Other","status":"marketed"},{"name":"pregabalin 450 mg","genericName":"pregabalin 450 mg","slug":"pregabalin-450-mg","indication":"Other","status":"marketed"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"MR-107A-02","genericName":"MR-107A-02","slug":"mr-107a-02","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"diazepam 20 mg","genericName":"diazepam 20 mg","slug":"diazepam-20-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"MR-107A-02","genericName":"MR-107A-02","slug":"mr-107a-02","phase":"phase_3","mechanism":"MR-107A-02 is a small molecule that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"gabapentin 600 mg","genericName":"gabapentin 600 mg","slug":"gabapentin-600-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"pregabalin 450 mg","genericName":"pregabalin 450 mg","slug":"pregabalin-450-mg","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPNThIcDlJU2xXVm5oWkVidUpZTkdwcVVvV1F0MjRWYjliN3ZrdUZOYXdiTTVOdmZVaDRVamM3V3NBenJKTHUwWmJJSkFiSTJIbWg4RGIwSWFwZFFHLVZ0Y2duN0tsNFNlLUszM1prVU03V2ozaEVaT0xyTzczd2pDRjE4VEtSa0ZXbXZZ0gFWQVVfeXFMT2pvRmxWNU14Rnl4alpzMDA2cHFtc3N3SGdPdGxDZDl3c2pnOHcxaGF6azRaRVhNNVRoQURCSUFLb21aWW1udXBHdUhOY0cwUWJ6TmFZRkE?oc=5","date":"2026-02-16","type":"pipeline","source":"Law360","summary":"Viagra Maker Wins 'Viagor Power' EU TM Battle - Law360","headline":"Viagra Maker Wins 'Viagor Power' EU TM Battle - Law360","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNeEo1eWJHck1GOEJtM3BOSHM3N2VPUjhpSjNTZWpsSEJ3cW1ENnJwY19TOHkwemNoMjRsdDB2aXliOS1NYWY4WUR4VGxiTmNhNlF5eU5JdlNCTVl0YUJIWWZ6eDZZQWVTaHpYeGdmd1lSX1ZZbmhSV1NlLWpJWE1aUmtMNHc?oc=5","date":"2026-01-30","type":"trial","source":"Market Data Forecast","summary":"U.S. Specialty Generics Market Size & Growth, 2034 - Market Data Forecast","headline":"U.S. Specialty Generics Market Size & Growth, 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOaGVYSmp3MFRiS1pQU1kxVmExOEhWZnVhU2hwblNSQ1pvZkJxYzRYeGNGbzc2Yy1oRzB3Z2Q4SllqVWt6el9jZG5CT01oSWFNdEdpZWVpaTFRSlpOaU5IYUQ5RlNjcEtMVHQ1ekZwbVpaREZ6Mmx4d1hVMVp2RU01OU5sX05VLWg5SlczeVY1UF94VEVXM25kaFlTTXY0dkdLc3VHcU41M1NDR3c1TktuX3lLWkFTNGlINVMwc25aQlAyaHptS2RPNm1USUJMcU9zRWx6MHFTdWxZeGZQeERIUHlwTFpUQ1NZMXfSAe8BQVVfeXFMT1REd2sxbU9GMU1nQW83alRidDZBUzhpRWREVTJhdm1DQk4tUkV0am9JaXJRQTFTZUhBRXI4bjZVajRsVjRwbnRDRnpsa2Rsc19pZl9lV1lmVVlFWDBqNThBeU1xOUEwX2J0YmxNTGxTQmE2Q2hsMVFsT3E0QkthdUxJLWMyY3Ntc2JyZGYwU0lfMmN0Z3A4YVM3dTR4RTc5ZTNhdmV1Y1VpNm5CdkNZb2VUcEdaeDYzcDJPWFhncEI5Z2VxQVk3SDRRRVNhR3RDTFBmVERRSXJvenN6VnowMmgya1ZXVnVhVFZJbWZmcEE?oc=5","date":"2024-03-05","type":"regulatory","source":"Medical Dialogues","summary":"Strides Pharma Science arm secures USFDA nod for Gabapentin tablets for neuropathic pain treatment - Medical Dialogues","headline":"Strides Pharma Science arm secures USFDA nod for Gabapentin tablets for neuropathic pain treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxPV056RkQ4SUdfdXpER3pIWGZadFB1NDlsUFhWanBzczdCSzdUSG42cTNTbklqSm5pdU1qZDB4dkllVERlNS14Y1Q5YTdxUFlSeDNaSWY2blpueEt6cFlyV0RsWlRBRzFOTXAtQkdFY3FxWlpNcGhSQ1Y2MjQ5Z0pCWGV3clRXVW1XLVQyS2NVYTBhQQ?oc=5","date":"2024-02-28","type":"deal","source":"Contract Pharma","summary":"Viatris and Idorsia Enter R&D Collaboration - Contract Pharma","headline":"Viatris and Idorsia Enter R&D Collaboration","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOdnBQQXdUTzJud2R5TUhQZnFhdGpDZUtmOFVRTy10ZUxaLUdTQ29TWS16MWZtVWRrQU03SVdHRVRMVlZSVmZra05Ld2hINWNZNGV4Y2xOMDBOVll0LUtVU296czlLUnNoSUYyNW9ueXBPZ0hCeFlLRjVnTTFQZ1VNZW85d3NZaG5zems1Y2ZsM1U3N3Z2ODFuU2E2U3ZnaUxwaHU0RtIBqgFBVV95cUxOak4yVE8yZl9BMXVOWndHMFFNNkFLQ0RSaGwyU2FsZ2NnYlBlZjJCalFmS051Qy1tUWt6OVN0QVlVWFB5TVJ6UmdWN2o4TFhXZUhkQzVWZTRINXFfRUZUNVZaQmdVM1VUaHF2LXZ5dldUd05FUy1CR2sxa3Z1YWlGMlE0VDV4a2tYU2FxRGE5SEVKY2Q4UXpmUEJjMmVEZkVUc0s2T044SGVNdw?oc=5","date":"2024-01-11","type":"regulatory","source":"Express Pharma","summary":"Unichem gets USFDA nod for Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg - Express Pharma","headline":"Unichem gets USFDA nod for Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQZWc3OTgyR09MaWFCcXFsX0F3WmxZeFV6YzRENFVDVHpILTlGcFpiRC1mdEFzZ1RCSlYxSFU1MDg5VmxnTjVXM0wwLS1vX2NwSF9BdDUzY2thUElSRWRpY3E2MF9SMGNYVzJqTm1oVUxVVHZycW1NMXhRdHpDWk54aklaOFZfUjJBZkQ4MmZkdU9Qd1U1ZWtwbDhLQU5nZw?oc=5","date":"2023-06-22","type":"pipeline","source":"Medical Professionals Reference","summary":"Liqrev, an Oral Suspension Formulation of Sildenafil, Now Available - MPR - Medical Professionals Reference","headline":"Liqrev, an Oral Suspension Formulation of Sildenafil, Now Available - MPR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMifEFVX3lxTE11aEVWU3J2dEtCRUNoaXZtWDlnRW1BZ3NadGljR3p1Y3liYnZibkx5Qm0xUFZnZ1ZNMTZDQmJPR1dEc1o2VGk3bmZuMHdqczVLbWRqdlgwam13dG5MZVBQWFlPeDY0SE1scUZLa0NxT1A1V18tWkt0aTNyZXo?oc=5","date":"2023-05-22","type":"patent","source":"Fortune Business Insights","summary":"Specialty Generics Market Size, Share & Trends | Report [2034] - Fortune Business Insights","headline":"Specialty Generics Market Size, Share & Trends | Report [2034]","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxQa3RtLUtaczBPS1lFVU5fMjBEU1lydVF5NW9xeUhNSjZibHlMNVBPQ0xxTkpOUVItcng2M2tob09Ta2JSM1AzV1VwRDNVT0s4dmxyaWZKUWJzZVF2enFCeWtvTjljU2RvRDRlU1pEYjBhZ25RcVBhMms1TFc3bXJoSjJZNVVnQzlacXo3ektRbTFCdlNMeGMxbktxVUhzejE3OVp4eU9XSVhZTGFDUHJlakpWVWhJdkpyUGhvNDlJSTRselZfT3c?oc=5","date":"2023-01-12","type":"pipeline","source":"Fierce Pharma","summary":"JPM23: Viatris lays out plans to become ophthalmology leader and pull down $1B in eye care sales - Fierce Pharma","headline":"JPM23: Viatris lays out plans to become ophthalmology leader and pull down $1B in eye care sales","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgFBVV95cUxPeHM4Rkc0WXgtSTZ0YzMwQ1BYcUFDa0dZTTFmMDFGYXBVX21yUzhIY1BZYVBTZk15cktlN1FvNzU1b0FCZ2F4SXJKY2J4V0JvaWZrZGh0MENWUTR1LUFiWmEtYVVFT3lPdW9kM3VrTC1TWlJnY3dmd2dSNEZLRzd0OV9RX1VmY1BDeENjR1hOZC1RTEdhcG1Ic09iQXRhY1BmUDM1VHBtWk84WXJnMHc?oc=5","date":"2022-09-29","type":"pipeline","source":"lupin.com","summary":"Lupin Launches Sildenafil for Oral Suspension in the United States - Lupin | Press Release - lupin.com","headline":"Lupin Launches Sildenafil for Oral Suspension in the United States - Lupin | Press Release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugFBVV95cUxOQktsaUdOeG1UeGt6YkRPX2tuRXlYdWpIRE9tanFKYVQ2V21wblRuMlNUTGExS1czN0ZhQ053aDN1SURZTGxEamh6Y2V6d25MbTlOUFJnOXFzWHBtUjRUVGpFbTJ3ZmxyVVMtVER2Rzh5WDI1VVZxRFRTNjRmNXI3RWpFRjI4bXQ5OGF0Z0dpVDBKTXZEaTlPRnNwd3ZZRkY3azViTzJrb0lMOEJjLWtkWWs1OUtncWo4Y2fSAb8BQVVfeXFMUEZBTUdyNUctUktxT0xMa29HUlpYQWRPV2JiZUd2d1VYRzVyc19tUW1zRm5SbXZ3REJHVGFIVHRJNzR3M0dLb0U4VnVNelBEQ29QY1lyRVJ0VVo0aUN0dHhaSDRlQVJDX0VBanlxWHB6WGc2MDFiTUJqMUp0UXNkdHpXSUZnRG1HWXV3WTJkZDlFV3g5dDUyVmVFblMwODBQUWFHa282SG13QmRpNzJrM3RsaVQ1NHhMZmNwaUFSMlk?oc=5","date":"2022-09-29","type":"patent","source":"ET HealthWorld","summary":"Lupin launches generic hypertension drug in US market - ET HealthWorld","headline":"Lupin launches generic hypertension drug in US market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQLU9RU05YXzdYRG0yWUxqMWtleWVXenp4MmRWM0ZETVc0Q0YxWm8zVkUwOU9Cc0xORkdoOTIzZHN0VFM1VTV1dXNrRmFiOGY4UmNUclVBd3RqbjdfQ2d0dWF3eXY2dU96eVhXNTFieDcwbXM4d0tpWTNBSy1GMjhXMHdGWmxsRFV5RWJpbWUxWTlPZw?oc=5","date":"2022-09-01","type":"patent","source":"DCAT Value Chain Insights","summary":"Company Moves: The Latest in the Global Generics Market - DCAT Value Chain Insights","headline":"Company Moves: The Latest in the Global Generics Market","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPcm5kWlRQUmM1MkxJSlhwSC1BOEpIWDh6VlZxTVZqdHZPeHItQi1EemxVUTVBRDkyN1JtTmJiekZkTGlraWNUa0JuUzZGekg0UG9DaWVSTGwxamU4ZnN0VGF5OVpBaWJIY2pQd3lwNzBPa1doM2JzTE1BNmUwSnBzUzc2Q3JVWndFb0RBM3NzWi1xX29GSDFGcmNJMy1GWnBuQlN1YmZyU2FJeFg4S1Q3SUs5Vl9zQQ?oc=5","date":"2019-11-12","type":"pipeline","source":"Fierce Pharma","summary":"Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before? - Fierce Pharma","headline":"Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"marketed":3,"phase_3":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}